Year: 2019
Type: dissertation
Study designs: Systematic Review, Meta-Analysis
Abstract: In a literature-based meta-analysis, we reported on the association of obesity at breast cancer (BC) diagnosis with disease-free (DFS) and overall survival (OS) in BC subtypes. We included 26 studies (108,793 patients) and the results showed pooled hazard ratios, HRs, for DFS and OS in obese vs non-obese were worse in all subgroups studied (ER/PgR+ve and HER2-ve; HER2+ve and any ER/PgR; and triple negative, TN), with larger prognostic effects in the ER/PgR and HER2-ve subtype. HRs for OS (but not DFS) were somewhat higher in observational vs interventional studies in ER/PgR+ve/HER2-ve and HER2+ve/ any ER/PgR but not in TN. This differential effect was statistically significant only in the HER2+ve subgroup and it may reflect the selection of healthier patients for intervention trials; obese patients in these studies may not have the same degree of obese physiology as the broader population. We evaluated the association of BMI, metabolic, inflammatory and tumor markers with CTCs in women with metastatic BC prior to a new systemic therapy. 96 patients with metastatic BC were recruited. ≥5 CTCs/7.5mL was detected in 43.8% of patients and those with liver metastases (vs. not) more frequently had an elevated CTC count. Some inflammatory markers were significantly associated with PAI-1, IL6, IL8, hs-CRP. CEA and CA15-3 were significantly higher in the CTC high (≥5 CTCs/7.5mL) versus in the CTC low group (
Source: TSpace (University of Toronto)
Author: Ana Elisa Lohmann
Language: English
Topic: Cancer Risks and Factors
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3159379128